Exhibit 4.14

AMENDMENT NO. 1 TO WARRANT

TO

PURCHASE COMMON STOCK

THIS AMENDMENT NO. 1 TO WARRANT TO PURCHASE COMMON STOCK (this Amendment) is entered into as of the 19thday of February
2009, by and between ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) and Atlas Venture Fund VII, L.P.

Recitals

A. The Holder was previously issued a Warrant to Purchase Common Stock dated as of October 10, 2008 (the Warrant).
Capitalized terms used in this Amendment, but not otherwise defined in this Amendment, shall have the meanings assigned to them in the Warrant.

B. The
Holder and ARCA biopharma, Inc., a Delaware corporation (f/k/a Nuvelo, Inc.) desire to amend the Warrant to reflect the closing of the Merger and the exchange of the common stock of the Corporation (as defined below) for the common stock of ARCA
biopharma Colorado, Inc., a Delaware corporation (f/k/a ARCA biopharma, Inc.) in connection with such closing.

Amendments

1. The definition of the term Exercise Price in Section 1(b) of the Warrant shall be deleted in its entirety and replaced with the
following:

(b)Exercise Price shall mean $9.7406, subject to adjustment pursuant to the terms of the
Warrant, including Section 5 of the Warrant.

2. The definition of the term Exercise Shares in Section 1(c) of the Warrant
shall be deleted in its entirety and replaced with the following:

(c)Exercise Shares shall mean 75,449
shares of common stock of the Corporation (the Common Stock) issuable upon the exercise of the Warrant, subject to adjustment pursuant to the terms of the Warrant, including Section 5 of the Warrant.

3. The following defined term shall be added to Section 1 of the Warrant:

(e)Corporation shall mean ARCA biopharma, Inc. a Delaware corporation (f/k/a Nuvelo, Inc.).

4. Except for revisions expressly set forth in this Amendment, the parties hereby ratify and confirm the terms of the Warrant in their entirety.



---

IN WITNESS WHEREOF, the undersigned have executed this Amendment to be effective as of the date first set
forth above.



|                     |  |                                             |  |                                                            |  |                        |  |                     
|-------------------- |  | ------------------------------------------- |  | ---------------------------------------------------------- |  | ---------------------- |  | --------------------
|Corporation:         |  |                                             |  | Holder:                                                   
|                     |  |                                            
|ARCA BIOPHARMA, INC. |  |                                             |  | Atlas Venture Fund VII, L.P.                              
|                     |  |                                            
|                     |  |                                             |  | By: Atlas Venture Associates VII, L.P. its
General Partner
|                     |  |                                            
|                     |  |                                             |  | By: Atlas Venture Associates VII, Inc. its
General Partner
|                     |  |                                             |  |                                                           
|By:                  |  | /s/ Christopher D. Ozeroff                  |  |                                                            |  | Signature:             |  | /s/ Kristen Laguerre
|                     |  | Christopher D. Ozeroff, Executive Vice      |  |                                                            |  | Name: Kristen Laguerre
|                     |  | of Business Development and General Counsel |  |                                                            |  | Title: Vice President